Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc(INBS)股票分析

$1.990

+0.260 (+13.07%)收盘时

Loading chart…
最高
2.000
开盘
1.750
成交量加权均价
1.90
成交量
73.60K
市值
5.83M
最低
1.720
成交额
140.09K
企业价值/息税折旧摊销前利润(TTM)
-0.15

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes.

ibs.inc

AI 分析 of Intelligent Bio Solutions Inc (INBS)

买入

Intelligent Bio Solutions Inc is a good buy right now due to its recent price increase of 13.07% over the last five days, indicating strong momentum. The RSI is at 74.51, suggesting it is overbought, but the stock has shown a significant recovery from its 52-week low of 1.35, currently trading at 1.99. The company has also secured FDA submission for its drug screening system, which could tap into a multi-billion-dollar market, providing a strong growth catalyst. However, the main risk is its high net loss of 3.91 million in Q4 2026, which could impact future profitability.

估值指标

Intelligent Bio Solutions Inc(INBS)当前预期市盈率为 0.00,5 年平均预期市盈率为 -1.23。

预期市盈率

合理
5 年均值 P/E
-1.23
当前P/E
0.00
高估
0.99
低估
-3.45

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
-0.01
当前EV/EBITDA
-0.15
高估
0.03
低估
-0.04

预期市销率

合理
5 年均值 P/S
9.23
当前P/S
0.74
高估
35.98
低估
-17.51

Alphio AI 对 INBS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%INBS

$2.95

情景价格

基

基准

基准 · 50%INBS

$2.44

情景价格

悲

悲观

悲观 · 25%INBS

$1.86

情景价格

事件时间线

2026-09-09 (ET)

09:00:00

Intelligent Bio Solutions Submits Drug Screening System to FDA

2026-09-01 (ET)

09:00:00

Intelligent Bio Solutions Enters Agreement to Issue 2,036,659 Shares

2026-08-11 (ET)

09:30:00

Intelligent Bio Solutions Completes Drug Screening Study

2026-07-21 (ET)

09:00:00

Intelligent Bio Solutions Completes Precision Testing

2026-06-02 (ET)

09:10:00

Intelligent Bio Solutions Initiates Multi-Site Study for FDA Submission

资讯

INBS 常见问题 —— 由 Alphio AI 解答

Intelligent Bio Solutions Inc. is a medical technology company focused on delivering intelligent, rapid, non-invasive testing solutions. The Company’s active product is the Intelligent Fingerprinting Platform, which consists of a portable platform that analyzes fingerprint sweat using a one-time cartridge and portable handheld reader. Its Intelligent Fingerprinting Drug Screening System (the IFP System) is a two-part system that consists of non-invasive, fingerprint sweat-based diagnostic testing products designed to detect drugs of abuse, including opiates, cocaine, methamphetamines, benzodiazepines, cannabis, methadone, and buprenorphine. The IFP System comprises a single-use tamper-evident drug screening cartridge for sample collection and the Intelligent Fingerprinting DSR-Plus portable analysis unit onto which ten fingerprint sweat samples are collected in under a minute before the portable analysis unit provides an on-screen result in under ten minutes. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Intelligent Bio Solutions Inc is a good buy right now due to its recent price increase of 13.07% over the last five days, indicating strong momentum. The RSI is at 74.51, suggesting it is overbought, but the stock has shown a significant recovery from its 52-week low of 1.35, currently trading at 1.99. The company has also secured FDA submission for its drug screening system, which could tap into a multi-billion-dollar market, providing a strong growth catalyst. However, the main risk is its high net loss of 3.91 million in Q4 2026, which could impact future profitability.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易